Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Inhibition of C-X-C chemokine receptor 2 (CXCR2)-mediated neutrophil recruitment as a targeted therapy in Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutated lung adenocarcinoma.

FY 2019-20

Summary
"Lung cancer is the deadliest cancer. More than 50% of patients are diagnosed when their cancer has already spread to other organs. It is hard to develop drugs that specifically recognize tumour cells since the differences between tumour and normal cells is nearly indistinguishable. For this reason, we have chosen to investigate how we can use the immune system to fight cancer.Cancer has evolved the ability to hide from the immune system. Although the immune system is thought to play a protective role, some immune cells, like neutrophils, favour tumour progression. Normally, neutrophils play a protective role as they are the first responders to sites of injury and inflammation. In the context of cancer, tumour cells attract and reprogram neutrophils to favor tumour growth and invasion into other organs. Therefore, we are investigating a drug that can block neutrophils from entering the tumour.To this end, our goal is to determine if we can prevent and/or reduce lung cancer progression by manipulating the immune system (i.e. preventing the invasion of neutrophils into the tumour).To test this goal, we are collaborating with scientists in the field of bioengineering to create devices to specifically model the way that lung cancer attracts neutrophils. Using physics to understand the movement of cells, a novel device was created to mimic neutrophil attraction to lung cancer cells. This device will allow us to determine which patients would benefit from this therapy.This drug has exciting potential for this patient cohort with very limited treatment options. Blocking neutrophil invasion is a therapy that is currently in clinical trials for chronic pulmonary diseases and some cancers, proving to be safe in humans."
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
428770
Name
De Meo Meghan
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Inhibition of C-X-C chemokine receptor 2 (CXCR2)-mediated neutrophil recruitment as a targeted therapy in Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutated lung adenocarcinoma.
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
C-X-C Chemokine Receptor 2 (Cxcr2); Cxcr2 Inhibition; Immune Checkpoint Inhibition; Immune Modulation; Immune-Mediated Cancer Regression; Kirsten Rat Sarcoma Viral Oncogene Homolog (Kras); Lung Adenocarcinoma; Neutrophil Recruitment; Targeted Therapy
Abstract
"Lung cancer is the deadliest cancer. More than 50% of patients are diagnosed when their cancer has already spread to other organs. It is hard to develop drugs that specifically recognize tumour cells since the differences between tumour and normal cells is nearly indistinguishable. For this reason, we have chosen to investigate how we can use the immune system to fight cancer.Cancer has evolved the ability to hide from the immune system. Although the immune system is thought to play a protective role, some immune cells, like neutrophils, favour tumour progression. Normally, neutrophils play a protective role as they are the first responders to sites of injury and inflammation. In the context of cancer, tumour cells attract and reprogram neutrophils to favor tumour growth and invasion into other organs. Therefore, we are investigating a drug that can block neutrophils from entering the tumour.To this end, our goal is to determine if we can prevent and/or reduce lung cancer progression by manipulating the immune system (i.e. preventing the invasion of neutrophils into the tumour).To test this goal, we are collaborating with scientists in the field of bioengineering to create devices to specifically model the way that lung cancer attracts neutrophils. Using physics to understand the movement of cells, a novel device was created to mimic neutrophil attraction to lung cancer cells. This device will allow us to determine which patients would benefit from this therapy.This drug has exciting potential for this patient cohort with very limited treatment options. Blocking neutrophil invasion is a therapy that is currently in clinical trials for chronic pulmonary diseases and some cancers, proving to be safe in humans."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
De Meo, Meghan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~